IC Data, Platform, and Migration Advisory
Vendor-neutral advisory to help pharma commercial teams own their IC data infrastructure, select and govern SPM platforms, and build the in-house capability to manage their programs without depending on black-box vendors.
The Problem NDL Solves
For many pharma commercial teams, the IC platform has become the problem rather than the solution. Vendors are expensive and opaque. Governance is unclear. Migration projects stall or go over budget. The internal team cannot validate payout calculations without going back to the vendor. And when leadership wants to understand why a rep is being paid what they are being paid, no one in-house can answer the question cleanly.
These are not software problems. They are data infrastructure and governance problems that show up through software.
- SPM platform costs keep rising with no clear ROI
- In-house team cannot validate IC calculations independently
- Migration from one platform to another has stalled or failed
- IC data is managed by the vendor rather than owned by the client
- New platform capabilities (including GenAI features in SPM tools) have not been evaluated
- Reporting out of the SPM platform conflicts with reporting from other commercial systems
- The platform selection decision was made without a clear capability requirements process
Core Offerings
IC Data and Platform Health Check
Assessment of IC data flows, platform architecture, calculation process, reporting outputs, vendor dependencies, control gaps, and modernization options. Produces a clear picture of what you own, what the vendor controls, where the highest-priority gaps are, and what a realistic modernization path looks like — including evaluation of GenAI capabilities in SPM platforms that most pharma IC teams have not yet assessed.
Duration: 4 to 6 weeks | Investment: $45,000 to $75,000
IC Data Migration and In-House Build Advisory
CPMAI-governed advisory for migrating from vendor-hosted to in-house IC infrastructure, or from one SPM platform to another. Covers vendor exit planning, data model design, rules library documentation, data lineage and source-to-report mapping, parallel-run validation, cutover governance, and post-migration stabilization. Structured across the six CPMAI phases to ensure the migration is reproducible, auditable, and leaves the client owning their program — not the vendor.
Duration: 12 to 24 weeks | Investment: $85,000 to $200,000
IC Calculation and Reporting Validation Sprint
A focused sprint to validate calculation logic, payout outputs, source-to-report lineage, dashboard consistency, and exception handling. Designed for organizations that need an independent validation of their IC calculations and reporting outputs — either as a standalone engagement or as a phase gate within a larger migration or redesign project.
Duration: 2 to 4 weeks | Investment: $20,000 to $45,000
Vendor-Neutral by Design
NDL does not resell software, take referral fees from SPM vendors, or have implementation partnerships that create any financial incentive to recommend one platform over another. Every platform recommendation is driven by your specific capability requirements, data environment, team structure, and total cost picture.
NDL brings working knowledge of the major SPM platforms used in pharma — including Xactly, Varicent, Anaplan, and others — as well as the emerging landscape of AI-enhanced IC capabilities. That working knowledge is applied in your interest, not the vendor’s.
Start with a Focused Diagnostic
Most IC data and platform engagements start with the IC Data and Platform Health Check — a structured audit that gives you a clear picture of where you stand before committing to a migration or selection process.